Qinlock

The active ingredient in Qinlock is ripretinib. Qinlock is an enzyme inhibitor and is part of the drug class of cancer medicines known as tyrosine kinase inhibitors. Its mechanism of action is to block the activity of receptors called KIT and PDGFRA on the surface of cancer cells. By stopping the enzyme, the use of Qinlock will stop cancer cells from growing and multiplying. This helps improve your progression-free survival (PFS), or the time from initial treatment to growth of the cancer or death.

Follow all directions given to you by your doctor and read all documents provided, including the full Prescribing Information, FDA-Approved Product Labeling, Instructions for Use, and Medication Guide before using Qinlock. However, the following is a synopsis of the general guidelines for the use of Qinlock:

• Take one tablet at the same time daily
• You can take your medication with or without food
• Swallow the tablets whole; do not chew, crush, or split the tablets
• Do not take an extra dose if you vomit your normal dose. Instead, speak to your healthcare provider
• Do not change your dosage unless your healthcare provider tells you to do so

The most common side effects of Qinlock seen in clinical trials as compared to placebo include:

• Alopecia (hair loss)
• Myalgia (muscle pain)
• Tiredness
• Diarrhea
• Decreased levels of phosphate
• Nausea
• Decreased appetite
• Abdominal pain
• Constipation
• Vomiting
• Headache
• Joint pain

Some individuals may experience serious side effects while using Qinlock. These side effects may require immediate medical attention. If you experience any of the following, contact your healthcare provider or seek emergency medical help:

• Palmar‑plantar erythrodysesthesia syndrome (PPES)
• New primary cutaneous malignancies, including:
• Skin cancers known as cutaneous squamous cell carcinoma, keratoacanthoma, or melanoma.
• Hypertension
• Cardiac dysfunction
• Tell your doctor right away if you experience any symptoms of cardiac failure, such as shortness of breath, swelling in your abdomen, or you’re feeling very tired.
• Risk of impaired wound healing
• Photosensitivity
• Let your healthcare provider know if you have any skin changes.
• Wear sunscreen whenever possible; Qinlock will make you burn more easily.

This is not the full list of adverse reactions, however, these were the ones found in the Invictus study. Invictus was a global, randomized, double‑blind, placebo‑controlled Phase 3 trial in patients who had an unresectable, locally advanced, or metastatic gastrointestinal stromal tumor (GIST), and who had been treated with at least three prior treatments. The primary efficacy outcome measure was progression-free survival (PFS). The secondary efficacy outcome was the overall survival rate. Talk to your oncology team about any concerns you may have.

You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Before starting Qinlock, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including if you have:

• Hypertension (high blood pressure)
• Heart problems
• A type of skin problem known as palmar-plantar erythrodysesthesia syndrome
• Had a recent surgery or plan to have surgery
• A pregnancy, plan to become pregnant, or are breastfeeding.

Hypersensitivity to ripretinib or any of its components.

Qinlock (ripretinib) may start showing effects within a few weeks of treatment, but it typically takes 1 to 2 months to assess its full benefits in managing gastrointestinal stromal tumors (GISTs). The response varies by individual, and your doctor will monitor your progress through regular check-ups and imaging.

When Qinlock is taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions, including:

• Strong CYP3A inhibitors
• Strong and moderate CYP3A inducers

Qinlock comes as a 50 mg tablet.

The recommended dose is usually 150mg daily with or without food until disease progression or unacceptable toxicity.

Store Qinlock at room temperature in its original container, away from moisture and light. Small excursions outside of room temperature are permitted.

Qinlock is manufactured by Deciphera Pharmaceuticals.

Currently, there is no generic available for Qinlock in the United States.

To stop taking Qinlock (ripretinib), consult your doctor first. They will guide you on the proper process, as stopping abruptly may affect your treatment. If you need to discontinue, your doctor may suggest tapering or switching to another treatment option. Always follow your healthcare provider’s instructions when discontinuing any medication.

Talk to your doctor if you are already pregnant or if you have any plans to become pregnant. They will know or recommend what is best for you.

Talk to your doctor if you are already breastfeeding or if you have any plans to breastfeed. They will know or recommend what is best for you.